BioAge develops a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging by using its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging.

Register for Details

For more details on financing and valuation of private companies similar to BioAge before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about BioAge

To invest in BioAge pre-IPO

Can you invest in BioAge pre-IPO?

You may invest in BioAge as it is a public company listed on the NASDAQ with ticker BIOA. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of BioAge before it goes public?

You can no longer sell shares of BioAge on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my BioAge shares?

Forge can no longer determine the value of BioAge shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is BioAge a publicly traded company?

BioAge became a public company following its IPO on 09/26/2024 and is now traded on the NASDAQ under the ticker BIOA.

To learn more about BioAge potential IPO

Will BioAge go IPO?

BioAge became a public company following its IPO on 09/26/2024 and is now traded on the NASDAQ under the ticker BIOA.

What is BioAge’s IPO price?

The IPO price of BioAge is not currently available.

When was BioAge founded?

BioAge was founded in 2015.

What is BioAge funding to date?

BioAge has raised $326.25MM to date.

Who are BioAge’s major investors?

Undisclosed Investors
Redpoint Ventures
Orbimed Advisors
Amgen Ventures
Pivotal Bioventure Partners
Rtw Investments
Orbimed
Lilly Ventures
Cormorant Asset Management
Felicis Ventures
Andreessen Horowitz
Ame Cloud Ventures
Springboard Enterprises
Sofinnova Investments
Longitude Capital
Sv Health Investors
Osage University Partners
Elad Gil
Khosla Ventures
Pear Ventures
Sands Capital
Pear Vc
Caffeinated Capital
Aarp Foundation
Kaiser Foundation Hospitals
Summit Peak Investments
Ra Capital
Summer Vc
Amgen
Green Sands Equity
Bossanova Investimentos
Phi-X Capital
Csc Upshot Ventures
Felicis
Ra Capital Management

BioAge Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
02/13/2024 Series D-1 $24.39MM $xx.xx $440.23MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
11,887,535
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
02/13/2024 Series D $170MM $xx.xx $440.23MM Sofinnova Investments, Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, Amgen Ventures, Andreessen Horowitz
Price per Share
$xx.xx
Shares Outstanding
49,713,403
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Sofinnova Investments, Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, Amgen Ventures, Andreessen Horowitz
12/03/2020 Series C $95MM $xx.xx $270.18MM Andreessen Horowitz, Elad Gil, Kaiser Foundation Hospitals, AARP Foundation, Phi-X Capital, Caffeinated Capital, Redpoint Ventures, PEAR Ventures, AME Cloud Ventures, Felicis Ventures
Price per Share
$xx.xx
Shares Outstanding
16,076,886
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Andreessen Horowitz, Elad Gil, Kaiser Foundation Hospitals, AARP Foundation, Phi-X Capital, Caffeinated Capital, Redpoint Ventures, PEAR Ventures, AME Cloud Ventures, Felicis Ventures
01/24/2019 Series B $22.93MM $xx.xx $86.05MM Felicis Ventures, Andreessen Horowitz, Caffeinated Capital, PEAR Ventures, AME Cloud Ventures, Khosla Ventures, Redpoint Ventures
Price per Share
$xx.xx
Shares Outstanding
7,455,241
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Felicis Ventures, Andreessen Horowitz, Caffeinated Capital, PEAR Ventures, AME Cloud Ventures, Khosla Ventures, Redpoint Ventures
07/28/2017 Series A-4 $54,998 $xx.xx $43.84MM Andreessen Horowitz, Felicis Ventures, AME Cloud Ventures, PEAR Ventures, Caffeinated Capital, Elad Gil
Price per Share
$xx.xx
Shares Outstanding
27,643
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Andreessen Horowitz, Felicis Ventures, AME Cloud Ventures, PEAR Ventures, Caffeinated Capital, Elad Gil
07/28/2017 Series A-3 $250,006 $xx.xx $43.84MM Andreessen Horowitz, Felicis Ventures, AME Cloud Ventures, PEAR Ventures, Caffeinated Capital, Elad Gil
Price per Share
$xx.xx
Shares Outstanding
203,821
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Andreessen Horowitz, Felicis Ventures, AME Cloud Ventures, PEAR Ventures, Caffeinated Capital, Elad Gil
07/28/2017 Series A-2 $1.81MM $xx.xx $43.84MM Andreessen Horowitz, Felicis Ventures, AME Cloud Ventures, PEAR Ventures, Caffeinated Capital, Elad Gil
Price per Share
$xx.xx
Shares Outstanding
2,948,071
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Andreessen Horowitz, Felicis Ventures, AME Cloud Ventures, PEAR Ventures, Caffeinated Capital, Elad Gil
07/28/2017 Series A-1 $11.82MM $xx.xx $43.84MM Andreessen Horowitz, Felicis Ventures, AME Cloud Ventures, PEAR Ventures, Caffeinated Capital, Elad Gil
Price per Share
$xx.xx
Shares Outstanding
4,753,466
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Andreessen Horowitz, Felicis Ventures, AME Cloud Ventures, PEAR Ventures, Caffeinated Capital, Elad Gil
Updated on: Nov 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.